Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, San Francisco
Study ID
NCT05746182
Status
Recruiting
Apply to this trial

Conditions

  • Pancreatic Neuroendocrine Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Hereditary Cancer Panel — DIAGNOSTIC_TEST
    UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes

Study Details

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)

Key Dates

Start date
Apr 7, 2023
Status verified
Jan 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Participants with Pancreatic Neuroendocrine Neoplasms

Primary Outcome Measure

Rate of overall pathogenic germline mutations [ Time Frame: Up to 2 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
University of California, Los AngelesLos AngelesCalifornia90095
Randy Hecht, MD (PRINCIPAL_INVESTIGATOR)
Univeristy of California, San DiegoSan DiegoCalifornia92093
Paul Fanta, MD (PRINCIPAL_INVESTIGATOR)
University of California, San FranciscoSan FranciscoCalifornia94143
Bryan Le
[email protected]
415-502-6313
[email protected]
877-827-3222
Emily Bergsland, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
University of California, Los Angeles· Los Angeles, CAUniveristy of California, San Diego· San Diego, CAUniversity of California, San Francisco· San Francisco, CA

Related Studies